Edition:
United Kingdom

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

2.40USD
22 Jan 2018
Change (% chg)

$0.12 (+5.26%)
Prev Close
$2.28
Open
$2.29
Day's High
$2.44
Day's Low
$2.24
Volume
71,381
Avg. Vol
113,483
52-wk High
$3.75
52-wk Low
$0.78

Chart for

About

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $34.19
Shares Outstanding(Mil.): 16.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

17 Jan 2018

BRIEF-Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore

* AETERNA ZENTARIS PROVIDES UPDATE ON LITIGATION AGAINST DAVID DODD AND PHILIP THEODORE

22 Dec 2017

BRIEF-David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris

* DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS

21 Dec 2017

Canada's Aeterna gets FDA approval for growth hormone deficiency test

Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency.

20 Dec 2017

Canada's Aeterna gets FDA approval for growth hormone deficiency test

Dec 20 Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency. The company said it intends to launch the test, Macrilen, in the United States during the first quarter of 2018.

20 Dec 2017

BRIEF-Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency

* AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY

20 Dec 2017

BRIEF-Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer

* AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER

08 Dec 2017

BRIEF-Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA

* AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY

27 Nov 2017

BRIEF-Aeterna Zentaris reports Q3 loss per share of $0.61

* Aeterna Zentaris reports third quarter 2017 financial and operating results

08 Nov 2017

BRIEF-Aeterna Zentaris announces appointment of interim chief financial officer

* Aeterna zentaris announces appointment of interim chief financial officer

25 Sep 2017

Earnings vs. Estimates